Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

IDH1-VAC (IDH1 R132H Peptide Vaccine)

STAR-VACC

German Cancer Research Center · Phase 2 · Not yet recruiting · Enrollment 216

NCT07888647

Catalyst Primary completion. 02.01.2034. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy

No efficacy figure is in this file for this study.